Caption Management’s Heron Therapeutics HRTX Stock Holding History

Caption Management’s Portfolio HRTX Stock Details HRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-339,100	Closed	-$441K	–	1761
2025 Q4	$441K	Buy	+339,100	New	+$419K	﹤0.01%	1262
2025 Q3	–	Sell	-1,505,900	Closed	-$3.12M	–	1829
2025 Q2	$3.12M	Buy	+1,505,900	New	+$3.08M	0.03%	566
2022 Q2	–	Sell	-133,300	Closed	-$763K	–	1612
2022 Q1	$763K	Sell	133,300 -7,900	-6%	-$57.8K	0.01%	1043
2021 Q4	$1.29M	Buy	+141,200	New	+$1.44M	0.01%	953
2021 Q2	–	Sell	-88,600	Closed	-$1.44M	–	1415
2021 Q1	$1.44M	Buy	+88,600	New	+$1.58M	0.03%	597
2020 Q2	–	Sell	-60,000	Closed	-$703K	–	1048
2020 Q1	$703K	Buy	+60,000	New	+$1.13M	0.04%	484

Other funds holding HRTX

RCMNY

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

Clearline Capital New York $1.68B AUM 53.07% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

VCIM

Velan Capital Investment Management Alpharetta, Georgia $164M AUM 542.31% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Tejara Capital London, United Kingdom $243M AUM 9.84% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

JAM

JW Asset Management Miami Beach, Florida $320M AUM 140.1% 1-Year Est. Return

Caption Management's HRTX Position: Q2 2026 in Review

Caption Management increased its Heron Therapeutics (HRTX) stake by 219% in Q2 2026, buying an estimated $550K and bringing the position to 1,000,000 shares worth $427K. The position accounts for ﹤0.01% of the portfolio, ranked #1356.

Caption Management first reported a position in HRTX in Q1 2019 and has held it in 10 quarters since. The position peaked at $3.19M in Q4 2021. 163 funds tracked by Wall St. Rank hold HRTX as of Q2 2026.

Caption Management held 1,000,000 shares of Heron Therapeutics worth $427K as of Q2 2026.
Caption Management bought 686,319 Heron Therapeutics shares in Q2 2026, an estimated $550K.
Heron Therapeutics made up ﹤0.01% of Caption Management's portfolio in Q2 2026, its #1356 holding.
Caption Management first reported a position in Heron Therapeutics in Q1 2019 and has held it in 10 quarters since.
Caption Management's Heron Therapeutics position peaked at $3.19M in Q4 2021.
163 funds tracked by Wall St. Rank held Heron Therapeutics as of Q2 2026.

Based on Caption Management's 13F filing for Q2 2026, filed 14 Aug 2026.